Literature DB >> 15651051

Lithium and valproate attenuate dextroamphetamine-induced changes in brain activation.

Emily C Bell1, Morgan C Willson, Alan H Wilman, Sanjay Dave, Sheila J Asghar, Peter H Silverstone.   

Abstract

BACKGROUND: Previous studies have suggested that both lithium and valproate may decrease phosphoinositol second messenger system (PI-cycle) activity. There is also evidence that dextroamphetamine may increase PI cycle activity. It was previously demonstrated that dextroamphetamine administration in volunteers causes a region and task dependent decrease in brain activation in healthy volunteers. The current study assessed the effect of 14 days pretreatment with lithium and valproate on these dextroamphetamine-induced changes in regional brain activity in healthy volunteers.
METHODS: This was a double-blind, placebo-controlled, study in which volunteers received either 1000 mg sodium valproate (n = 12), 900 mg lithium (n = 9) or placebo (n = 12). Functional images were acquired using functional magnetic resonance imaging (fMRI) while subjects performed three cognitive tasks, a word generation paradigm, a spatial attention task and a working memory task. fMRI was carried out both before and after administration of dextroamphetamine (25 mg). Changes in the number of activated pixels and changes in the magnitude of the blood-oxygen-level-dependent (BOLD) signal after dextroamphetamine administration were then determined.
RESULTS: In keeping with previous findings dextroamphetamine administration decreased regional brain activation in all three tasks. Pretreatment with lithium attenuated changes in the word generation paradigm and the spatial attention task, while pretreatment with valproate attenuated the changes in the working memory task.
CONCLUSIONS: These results suggest that both lithium and valproate can significantly attenuate dextroamphetamine-induced changes in brain activity in a task dependent and region specific manner. This is the first human evidence to suggest that both lithium and valproate may have a similar effect on regional brain activation, conceivably via similar effects on PI-cycle activity. 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15651051     DOI: 10.1002/hup.665

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  6 in total

1.  Functional connectivity between ventral prefrontal cortex and amygdala at low frequency in the resting state in bipolar disorder.

Authors:  Lara G Chepenik; Mariella Raffo; Michelle Hampson; Cheryl Lacadie; Fei Wang; Monique M Jones; Brian Pittman; Pawel Skudlarski; Hilary P Blumberg
Journal:  Psychiatry Res       Date:  2010-05-20       Impact factor: 3.222

Review 2.  Potential mechanisms of action of lithium in bipolar disorder. Current understanding.

Authors:  Gin S Malhi; Michelle Tanious; Pritha Das; Carissa M Coulston; Michael Berk
Journal:  CNS Drugs       Date:  2013-02       Impact factor: 5.749

Review 3.  Mitochondrial dysfunction and psychiatric disorders.

Authors:  Gislaine T Rezin; Graziela Amboni; Alexandra I Zugno; João Quevedo; Emilio L Streck
Journal:  Neurochem Res       Date:  2008-11-01       Impact factor: 3.996

4.  Chronic lithium treatment rectifies maladaptive dopamine release in the nucleus accumbens.

Authors:  Adem Can; Douglas O Frost; Roger Cachope; Joseph F Cheer; Todd D Gould
Journal:  J Neurochem       Date:  2016-10-18       Impact factor: 5.372

5.  Na+,K+-ATPase activity in an animal model of mania.

Authors:  Alexandra I Zugno; Samira S Valvassori; Emilene B S Scherer; Cristiane Mattos; Cristiane Matté; Camila L Ferreira; Gislaine T Rezin; Angela T S Wyse; João Quevedo; Emilio L Streck
Journal:  J Neural Transm (Vienna)       Date:  2009-03-03       Impact factor: 3.575

6.  Valproate reopens critical-period learning of absolute pitch.

Authors:  Judit Gervain; Bradley W Vines; Lawrence M Chen; Rubo J Seo; Takao K Hensch; Janet F Werker; Allan H Young
Journal:  Front Syst Neurosci       Date:  2013-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.